Company intelligence / Profile preview

SeraNovo

Leiden, South Holland, Netherlandsseranovo.com ↗

Ownership: Private
Employees: ~19
Development stage: Other

Overview

SeraNovo has demonstrated that its proprietary deep eutectic solvent formulations can significantly enhance the oral bioavailability of poorly soluble small molecules and peptides. Case studies include glibenclamide and atazanavir, where bioavailability improvements exceeded those achieved by traditional amorphous solid dispersions[2]. The company's platforms are used in multiple partner programs progressing through clinical phases[6].

Modalities: Small moleculePeptides (as formulation targets, not as a therapeutic developer)
Industry: Drug Discovery Services

Partnerships

AstraZeneca (multi-compound deal to enhance bioavailability using SeraNovo's technology)

Beyond the preview

Go deeper on SeraNovo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SeraNovo.

Explore the full profile